Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - ...
In the same month, the FDA also approved Dupixent as an add-on maintenance treatment for adolescent patients aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP ...
Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic inflammation. While these benign growths themselves are not harmful ...
GlobalData on MSN4d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialA Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...
the majority of whom will exhibit markers of type 2 inflammation. These patients have high corticosteroid exposure and often experience recurrence of nasal polyps following surgery. We’re very ...
GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated ... adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The studies evaluated ...
The ANCHOR-1 and ANCHOR-2 trials together recruited a total of 528 patients with chronic rhinosinusitis with nasal polyps (CRSwNP)—an inflammatory disease of the nose sinuses that obstructs ...
Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback